Literature DB >> 27825106

Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin.

Tania Brocks1,2, Oleg Fedorchenko1,2, Nicola Schliermann1,2, Astrid Stein3, Ute M Moll4,5, Seth Seegobin6, Manfred Dewor7, Michael Hallek1,2, Yvonne Marquardt8, Katharina Fietkau8, Ruth Heise8, Sebastian Huth8, Herbert Pfister9, Juergen Bernhagen7,10,11, Richard Bucala12, Jens M Baron8, Guenter Fingerle-Rowson13,2.   

Abstract

The response of the skin to harmful environmental agents is shaped decisively by the status of the immune system. Keratinocytes constitutively express and secrete the chemokine-like mediator, macrophage migration inhibitory factor (MIF), more strongly than dermal fibroblasts, thereby creating a MIF gradient in skin. By using global and epidermis-restricted Mif-knockout (Mif-/- and K14-Cre+/tg; Miffl/fl) mice, we found that MIF both recruits and maintains antigen-presenting cells in the dermis/epidermis. The reduced presence of antigen-presenting cells in the absence of MIF was associated with accelerated and increased formation of nonmelanoma skin tumors during chemical carcinogenesis. Our results demonstrate that MIF is essential for maintaining innate immunity in skin. Loss of keratinocyte-derived MIF leads to a loss of control of epithelial skin tumor formation in chemical skin carcinogenesis, which highlights an unexpected tumor-suppressive activity of MIF in murine skin.-Brocks, T., Fedorchenko, O., Schliermann, N., Stein, A., Moll, U. M., Seegobin, S., Dewor, M., Hallek, M., Marquardt, Y., Fietkau, K., Heise, R., Huth, S., Pfister, H., Bernhagen, J., Bucala, R., Baron, J. M., Fingerle-Rowson, G. Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin. © FASEB.

Entities:  

Keywords:  CD44; CD74; DMBA/TPA; chemokine; skin carcinogenesis

Mesh:

Substances:

Year:  2016        PMID: 27825106      PMCID: PMC6137604          DOI: 10.1096/fj.201600860R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  60 in total

Review 1.  Autoimmune diseases: MIF as a therapeutic target.

Authors:  Dorothee Greven; Lin Leng; Richard Bucala
Journal:  Expert Opin Ther Targets       Date:  2010-03       Impact factor: 6.902

2.  Macrophage migration inhibitory factor is essential for eosinophil recruitment in allergen-induced skin inflammation.

Authors:  Yoko Yoshihisa; Teruhiko Makino; Kenji Matsunaga; Ayumi Honda; Osamu Norisugi; Riichiro Abe; Hiroshi Shimizu; Tadamichi Shimizu
Journal:  J Invest Dermatol       Date:  2010-12-30       Impact factor: 8.551

3.  Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1.

Authors:  R Kleemann; A Hausser; G Geiger; R Mischke; A Burger-Kentischer; O Flieger; F J Johannes; T Roger; T Calandra; A Kapurniotu; M Grell; D Finkelmeier; H Brunner; J Bernhagen
Journal:  Nature       Date:  2000-11-09       Impact factor: 49.962

4.  MIF loss impairs Myc-induced lymphomagenesis.

Authors:  F Talos; P Mena; G Fingerle-Rowson; U Moll; O Petrenko
Journal:  Cell Death Differ       Date:  2005-10       Impact factor: 15.828

5.  Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.

Authors:  H Lue; M Thiele; J Franz; E Dahl; S Speckgens; L Leng; G Fingerle-Rowson; R Bucala; B Lüscher; J Bernhagen
Journal:  Oncogene       Date:  2007-02-19       Impact factor: 9.867

6.  Expression and induction of cytochrome p450 isoenzymes in human skin equivalents.

Authors:  M M Neis; A Wendel; T Wiederholt; Y Marquardt; S Joussen; J M Baron; H F Merk
Journal:  Skin Pharmacol Physiol       Date:  2010-01-14       Impact factor: 3.479

7.  Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene.

Authors:  B Ruggeri; M DiRado; S Y Zhang; B Bauer; T Goodrow; A J Klein-Szanto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

8.  Identification of macrophage migration inhibitory factor (MIF) in human skin and its immmunohistochemical localization.

Authors:  T Shimizu; A Ohkawara; J Nishihira; W Sakamoto
Journal:  FEBS Lett       Date:  1996-03-04       Impact factor: 4.124

9.  Deficient deletion of apoptotic cells by macrophage migration inhibitory factor (MIF) overexpression accelerates photocarcinogenesis.

Authors:  Ayumi Honda; Riichiro Abe; Yoko Yoshihisa; Teruhiko Makino; Kenji Matsunaga; Jun Nishihira; Hiroshi Shimizu; Tadamichi Shimizu
Journal:  Carcinogenesis       Date:  2009-07-07       Impact factor: 4.944

10.  Macrophage migration inhibitory factor promotes intestinal tumorigenesis.

Authors:  Jonathan M Wilson; P Louise Coletta; Richard J Cuthbert; Nigel Scott; Kenneth MacLennan; Gillian Hawcroft; Lin Leng; Jodi B Lubetsky; Kai K Jin; Elias Lolis; Francisco Medina; Jose A Brieva; Richard Poulsom; Alexander F Markham; Richard Bucala; Mark A Hull
Journal:  Gastroenterology       Date:  2005-11       Impact factor: 22.682

View more
  11 in total

1.  Expression Patterns of Macrophage Migration Inhibitory Factor and Its Gene Variants (MIF-173 G˃C) in Verruca Vulgaris.

Authors:  Mohammed H Hassan; Sawsan Abuhamdah; Bakheet E M Elsadek; Ashraf Abdelwahab; Tarek Hamdy Abd-Elhamid; Hanan M Fayed; Amany Abbass; Ahmed Alamir Mahmoud Abdallah; Marwa Mohamed; Wafaa Mohamed Abd-Elmagid
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-06-10

2.  The Fate of a Hapten - From the Skin to Modification of Macrophage Migration Inhibitory Factor (MIF) in Lymph Nodes.

Authors:  Isabella Karlsson; Kristin Samuelsson; Carl Simonsson; Anna-Lena Stenfeldt; Ulrika Nilsson; Leopold L Ilag; Charlotte Jonsson; Ann-Therese Karlberg
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

3.  Assessment of macrophage migration inhibitory factor in patients with verruca vulgaris.

Authors:  Neveen Emad Sorour; Ahmed Mohamed Hamed; Hala Abd-El Mageed Tabl; Amira Abd-El Aziz Ahmed
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-08-22

4.  Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer.

Authors:  Luisa Klemke; Tiago De Oliveira; Daria Witt; Nadine Winkler; Hanibal Bohnenberger; Richard Bucala; Lena-Christin Conradi; Ramona Schulz-Heddergott
Journal:  Cell Death Dis       Date:  2021-02-04       Impact factor: 8.469

5.  Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations.

Authors:  Daniel Heinrichs; Elisa F Brandt; Petra Fischer; Janine Köhncke; Theresa H Wirtz; Nurdan Guldiken; Sonja Djudjaj; Peter Boor; Daniela Kroy; Ralf Weiskirchen; Richard Bucala; Hermann E Wasmuth; Pavel Strnad; Christian Trautwein; Jürgen Bernhagen; Marie-Luise Berres
Journal:  Cells       Date:  2021-01-28       Impact factor: 6.600

6.  Haptenation of Macrophage Migration Inhibitory Factor: A Potential Biomarker for Contact Hypersensitivity.

Authors:  Lorena Ndreu; Samantha Sasse; Ann-Therese Karlberg; Isabella Karlsson
Journal:  Front Toxicol       Date:  2022-04-06

7.  Serum Levels of Migration Inhibitory Factor (MIF) and In Situ Expression of MIF and Its Receptor CD74 in Lepromatous Leprosy Patients: A Preliminary Report.

Authors:  Marco Alonso Martinez-Guzman; Anabell Alvarado-Navarro; Vidal Delgado-Rizo; Alejandra Garcia-Orozco; Jorge Arturo Mayorga-Rodríguez; Ana Laura Pereira-Suarez; Mary Fafutis-Morris
Journal:  Front Immunol       Date:  2018-02-13       Impact factor: 7.561

8.  Spatial and Single-Cell Transcriptional Profiling Identifies Functionally Distinct Human Dermal Fibroblast Subpopulations.

Authors:  Christina Philippeos; Stephanie B Telerman; Bénédicte Oulès; Angela O Pisco; Tanya J Shaw; Raul Elgueta; Giovanna Lombardi; Ryan R Driskell; Mark Soldin; Magnus D Lynch; Fiona M Watt
Journal:  J Invest Dermatol       Date:  2018-01-31       Impact factor: 8.551

9.  Macrophage Migration Inhibitory Factor (MIF) Drives Murine Psoriasiform Dermatitis.

Authors:  Siegfried Bezdek; Lin Leng; Hauke Busch; Sadegh Mousavi; Dirk Rades; Markus Dahlke; Detlef Zillikens; Richard Bucala; Christian D Sadik
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

10.  Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.

Authors:  Devalingam Mahalingam; Manish R Patel; Jasgit C Sachdev; Lowell L Hart; Niels Halama; Ramesh K Ramanathan; John Sarantopoulos; Dirk Völkel; Ashraf Youssef; Floris A de Jong; Apostolia Maria Tsimberidou
Journal:  Br J Clin Pharmacol       Date:  2020-04-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.